JP2016512425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512425A5 JP2016512425A5 JP2016501017A JP2016501017A JP2016512425A5 JP 2016512425 A5 JP2016512425 A5 JP 2016512425A5 JP 2016501017 A JP2016501017 A JP 2016501017A JP 2016501017 A JP2016501017 A JP 2016501017A JP 2016512425 A5 JP2016512425 A5 JP 2016512425A5
- Authority
- JP
- Japan
- Prior art keywords
- binding polypeptide
- glycan
- residue
- domain
- effector moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 150000004676 glycans Chemical class 0.000 claims 12
- 239000012636 effector Substances 0.000 claims 11
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 125000005629 sialic acid group Chemical group 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 239000002619 cytotoxin Substances 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 101710112752 Cytotoxin Proteins 0.000 claims 2
- 125000003172 aldehyde group Chemical group 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002923 oximes Chemical class 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000002068 Glycopeptides Human genes 0.000 claims 1
- 108010015899 Glycopeptides Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229930182830 galactose Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361776710P | 2013-03-11 | 2013-03-11 | |
| US201361776715P | 2013-03-11 | 2013-03-11 | |
| US201361776724P | 2013-03-11 | 2013-03-11 | |
| US61/776,710 | 2013-03-11 | ||
| US61/776,724 | 2013-03-11 | ||
| US61/776,715 | 2013-03-11 | ||
| PCT/US2014/022623 WO2014164503A1 (en) | 2013-03-11 | 2014-03-10 | Hyperglycosylated binding polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019040108A Division JP7121675B2 (ja) | 2013-03-11 | 2019-03-06 | 高グリコシル化結合性ポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512425A JP2016512425A (ja) | 2016-04-28 |
| JP2016512425A5 true JP2016512425A5 (enExample) | 2017-04-06 |
| JP6739330B2 JP6739330B2 (ja) | 2020-08-12 |
Family
ID=50543307
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501017A Active JP6739330B2 (ja) | 2013-03-11 | 2014-03-10 | 高グリコシル化結合性ポリペプチド |
| JP2016501047A Active JP6588422B2 (ja) | 2013-03-11 | 2014-03-10 | 糖類工学による部位特異的抗体−薬物コンジュゲーション |
| JP2019040108A Active JP7121675B2 (ja) | 2013-03-11 | 2019-03-06 | 高グリコシル化結合性ポリペプチド |
| JP2019165052A Active JP7021159B2 (ja) | 2013-03-11 | 2019-09-11 | 糖類工学による部位特異的抗体－薬物コンジュゲーション |
| JP2021068088A Active JP7321206B2 (ja) | 2013-03-11 | 2021-04-14 | 高グリコシル化結合性ポリペプチド |
| JP2022014608A Active JP7390414B2 (ja) | 2013-03-11 | 2022-02-02 | 糖類工学による部位特異的抗体－薬物コンジュゲーション |
| JP2023075428A Pending JP2023099146A (ja) | 2013-03-11 | 2023-05-01 | 高グリコシル化結合性ポリペプチド |
| JP2023195664A Active JP7650943B2 (ja) | 2013-03-11 | 2023-11-17 | 糖類工学による部位特異的抗体－薬物コンジュゲーション |
| JP2025037867A Pending JP2025090711A (ja) | 2013-03-11 | 2025-03-11 | 糖類工学による部位特異的抗体－薬物コンジュゲーション |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501047A Active JP6588422B2 (ja) | 2013-03-11 | 2014-03-10 | 糖類工学による部位特異的抗体−薬物コンジュゲーション |
| JP2019040108A Active JP7121675B2 (ja) | 2013-03-11 | 2019-03-06 | 高グリコシル化結合性ポリペプチド |
| JP2019165052A Active JP7021159B2 (ja) | 2013-03-11 | 2019-09-11 | 糖類工学による部位特異的抗体－薬物コンジュゲーション |
| JP2021068088A Active JP7321206B2 (ja) | 2013-03-11 | 2021-04-14 | 高グリコシル化結合性ポリペプチド |
| JP2022014608A Active JP7390414B2 (ja) | 2013-03-11 | 2022-02-02 | 糖類工学による部位特異的抗体－薬物コンジュゲーション |
| JP2023075428A Pending JP2023099146A (ja) | 2013-03-11 | 2023-05-01 | 高グリコシル化結合性ポリペプチド |
| JP2023195664A Active JP7650943B2 (ja) | 2013-03-11 | 2023-11-17 | 糖類工学による部位特異的抗体－薬物コンジュゲーション |
| JP2025037867A Pending JP2025090711A (ja) | 2013-03-11 | 2025-03-11 | 糖類工学による部位特異的抗体－薬物コンジュゲーション |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US9701753B2 (enExample) |
| EP (5) | EP2983701A2 (enExample) |
| JP (9) | JP6739330B2 (enExample) |
| KR (6) | KR20240023184A (enExample) |
| CN (4) | CN105189555B (enExample) |
| AU (5) | AU2014249224B2 (enExample) |
| BR (2) | BR112015020315A2 (enExample) |
| CA (2) | CA2902525C (enExample) |
| HK (1) | HK1214501A1 (enExample) |
| IL (7) | IL289918B2 (enExample) |
| MX (3) | MX370679B (enExample) |
| RU (2) | RU2711935C2 (enExample) |
| SG (3) | SG10201809779RA (enExample) |
| WO (2) | WO2014164503A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8528728B2 (en) | 2010-05-19 | 2013-09-10 | Johnson & Johnson Vision Care, Inc. | Ophthalmic lens disinfecting storage case |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| IL289918B2 (en) | 2013-03-11 | 2025-07-01 | Genzyme Corp | Site-specific antibody-drug conjugation through glycoengineering |
| HRP20230260T1 (hr) * | 2014-03-19 | 2023-04-28 | Genzyme Corporation | Glikoinženjering ciljajućih dijelova specifičan za mjesto |
| SG11201702786RA (en) * | 2014-10-09 | 2017-05-30 | Genzyme Corp | Glycoengineered antibody drug conjugates |
| NZ734803A (en) * | 2015-01-23 | 2023-03-31 | Sanofi Sa | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| CN108449940B (zh) | 2015-07-12 | 2021-06-08 | 杭州多禧生物科技有限公司 | 与细胞结合分子的共轭偶联的桥连接体 |
| WO2017176648A1 (en) | 2016-04-04 | 2017-10-12 | Rutgers, The State University Of New Jersey | Topoisomerase poisons |
| CN106248971B (zh) * | 2016-08-19 | 2017-10-03 | 合肥瀚科迈博生物技术有限公司 | 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途 |
| CN116143678A (zh) | 2016-11-14 | 2023-05-23 | 杭州多禧生物科技有限公司 | 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用 |
| HUE065241T2 (hu) | 2016-12-19 | 2024-05-28 | Medimmune Ltd | LIF elleni antitestek és alkalmazásaik |
| WO2018115960A1 (en) | 2016-12-19 | 2018-06-28 | Mosaic Biomedicals, S.L. | Antibodies against lif and uses thereof |
| WO2018126092A1 (en) | 2016-12-29 | 2018-07-05 | Development Center For Biotechnology | Processes for preparing glycoprotein-drug conjugates |
| WO2018178277A1 (en) | 2017-03-29 | 2018-10-04 | Avicenna Oncology Gmbh | New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof |
| CN111212569B (zh) | 2017-08-31 | 2025-01-24 | 辛格隆股份公司 | 用于制备细菌素和抗微生物肽的方法和组合物 |
| KR102110182B1 (ko) * | 2017-09-20 | 2020-05-14 | 한양대학교 에리카산학협력단 | 신규한 옥심 유도체 화합물 및 이를 포함한 항체-약물 복합체 |
| US11591408B2 (en) * | 2017-11-09 | 2023-02-28 | National Research Council Of Canada | Antibody glycoconjugates and methods of production and use |
| FR3085952B1 (fr) | 2018-09-17 | 2020-10-30 | Centre Nat Rech Scient | Conjugue anticorps-medicament comprenant des derives de quinoline |
| CN120192414A (zh) | 2019-04-03 | 2025-06-24 | 建新公司 | 具有降低的断裂的抗αβTCR结合多肽 |
| AU2019452577B2 (en) | 2019-06-29 | 2023-08-24 | Hangzhou Dac Biotech Co., Ltd. | Cell-binding molecule-Tubulysin derivative conjugate and preparation method therefor |
| PL3865155T3 (pl) * | 2020-02-13 | 2023-01-30 | Orano Med | Sposób miejscowo-specyficznego modyfikowania przeciwciała |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| KR102341642B1 (ko) | 2021-06-24 | 2021-12-21 | 주식회사 글로브 | 플로어용 영상 표출 시스템 |
| KR20240095442A (ko) | 2021-11-03 | 2024-06-25 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 항체의 특이적 접합 |
| KR20240133715A (ko) * | 2021-12-17 | 2024-09-04 | 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 | Claudin18.2를 표적으로 하는 항체-약물 접합체 |
| WO2025088546A1 (en) | 2023-10-25 | 2025-05-01 | Ablynx N.V. | Fc domain variants with enhanced fc receptor binding |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| ATE159982T1 (de) | 1988-09-15 | 1997-11-15 | Univ Columbia | Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung |
| JP2650358B2 (ja) | 1988-10-06 | 1997-09-03 | 株式会社ニコン | 半透過部材を有する光学装置 |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| US5622929A (en) * | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| US5792456A (en) * | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
| ES2167391T3 (es) * | 1994-09-16 | 2002-05-16 | Merck Patent Gmbh | Inmunoconjugados ii. |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| SE9601245D0 (sv) | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
| WO1997034632A1 (en) * | 1996-03-20 | 1997-09-25 | Immunomedics, Inc. | Glycosylated humanized b-cell specific antibodies |
| ATE386809T1 (de) | 1996-08-02 | 2008-03-15 | Bristol Myers Squibb Co | Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| DE69840412D1 (de) | 1997-10-31 | 2009-02-12 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| US6953675B2 (en) | 1997-11-06 | 2005-10-11 | Immunomedics, Inc. | Landscaped antibodies and antibody fragments for clinical use |
| US6001817A (en) * | 1998-01-12 | 1999-12-14 | Unitech Pharmaceuticals, Inc. | Pharmaceutical composition comprised of cisplatin, and processes for making and using same |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU3369999A (en) | 1998-04-02 | 1999-10-25 | Genentech Inc. | Antibody variants and fragments thereof |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| AU6059699A (en) * | 1998-09-23 | 2000-04-10 | Regents Of The University Of California, The | Synthetic peptides, conjugation reagents and methods |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| US7304031B2 (en) | 2001-10-29 | 2007-12-04 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
| CN1110322C (zh) * | 1999-07-21 | 2003-06-04 | 中国医学科学院医药生物技术研究所 | 单克隆抗体Fab'－平阳霉素偶联物及其抗肿瘤作用 |
| WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US20050107595A1 (en) | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| WO2004099231A2 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US7265084B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US7226903B2 (en) * | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
| US7795210B2 (en) * | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| US7173003B2 (en) * | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7696163B2 (en) * | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| DK2279755T3 (da) | 2001-10-10 | 2014-05-26 | Ratiopharm Gmbh | Remodellering og glycokonjugering af fibroblastvækstfaktor (FGF) |
| US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| CA2478011C (en) | 2002-03-01 | 2013-05-21 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
| US20070207142A1 (en) * | 2002-05-08 | 2007-09-06 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| DK1534335T4 (en) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| CN101987871A (zh) | 2002-09-27 | 2011-03-23 | 赞科股份有限公司 | 优化的Fc变体及其产生方法 |
| WO2004035752A2 (en) | 2002-10-15 | 2004-04-29 | Protein Design Labs, Inc. | ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS |
| ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| JP4629047B2 (ja) | 2003-06-12 | 2011-02-09 | イーライ リリー アンド カンパニー | Ｇｌｐ−１アナログ複合タンパク質 |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| RU2392324C2 (ru) | 2003-09-18 | 2010-06-20 | Симфоген А/С | Способ связывания интересующих последовательностей |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| PL2489364T3 (pl) * | 2003-11-06 | 2015-06-30 | Seattle Genetics Inc | Związki monometylowaliny zdolne do sprzęgania do przeciwciał |
| EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| US7001978B2 (en) | 2003-11-19 | 2006-02-21 | Xerox Corporation | Unsaturated ester substituted polymers with reduced halogen content |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| EP1765853B1 (en) * | 2004-01-08 | 2015-10-28 | ratiopharm GmbH | O-linked glycosylation of G-CSF peptides |
| CA2552788C (en) | 2004-01-12 | 2013-09-24 | Applied Molecular Evolution, Inc. | Fc region variants |
| WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2565414A1 (en) | 2004-05-04 | 2005-11-24 | Novo Nordisk Health Care Ag | O-linked glycoforms of polypeptides and method to manufacture them |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| BRPI0516284A (pt) * | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| EP1799700A4 (en) | 2004-09-27 | 2009-02-11 | Centocor Inc | SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| JP4829609B2 (ja) | 2004-12-22 | 2011-12-07 | 独立行政法人科学技術振興機構 | ヒト抗体酵素およびその生産方法 |
| WO2006090119A1 (en) | 2005-02-23 | 2006-08-31 | Lipoxen Technologies Limited | Activated sialic acid derivatives for protein derivatisation and conjugation |
| ES2432091T5 (es) | 2005-03-25 | 2022-03-18 | Gitr Inc | Moléculas de unión GITR y usos de las mismas |
| WO2006105338A2 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するＦｃ変異体 |
| EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
| EP1907001B1 (en) | 2005-06-17 | 2015-07-15 | Merck Sharp & Dohme Corp. | Ilt3 binding molecules and uses therefor |
| EP1896071B1 (en) | 2005-06-30 | 2015-04-29 | Janssen Biotech, Inc. | Methods and compositions with enhanced therapeutic activity |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| NZ572177A (en) * | 2006-06-06 | 2012-02-24 | Genentech Inc | Anti-dll4 antibodies and methods using same |
| US8580511B2 (en) * | 2006-06-19 | 2013-11-12 | The Regents Of The University Of California | Two-color fluorescent reporter for alternative pre-mRNA splicing |
| AU2007345745C1 (en) | 2006-06-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
| US7833260B2 (en) | 2006-07-20 | 2010-11-16 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
| CN101516388B (zh) * | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
| RU2460543C2 (ru) | 2006-10-04 | 2012-09-10 | Ново Нордиск А/С | Глицерин-связанные пэгилированные сахара и гликопептиды |
| FI20060946A0 (fi) | 2006-10-26 | 2006-10-26 | Glykos Finland Oy | Influenssaviruksen nukleiinihappoja ja peptidejä |
| JP2010512306A (ja) * | 2006-10-27 | 2010-04-22 | ザ ロックフェラー ユニバーシティー | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| CL2007003411A1 (es) | 2006-11-28 | 2008-07-04 | Centelion | Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu |
| SI2068887T1 (sl) | 2007-01-09 | 2014-06-30 | Biogen Idec Ma Inc. | SP35 protitelesa in njihova uporaba |
| EP2125893A2 (en) | 2007-01-23 | 2009-12-02 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| CN101687037B (zh) | 2007-05-08 | 2013-07-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗muc16抗体和抗体药物偶联物 |
| EP2205258B1 (en) * | 2007-09-28 | 2017-05-24 | Janssen Biotech, Inc. | Methods and structural conformations of antibody preparations with increased resistance to proteases |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| ES2450755T3 (es) | 2007-10-19 | 2014-03-25 | Genentech, Inc. | Anticuerpos anti-TENB2 modificados por ingeniería genética con cisteína, y conjugados de anticuerpo y fármaco |
| EP2242505A4 (en) * | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
| PT2247620T (pt) * | 2008-01-31 | 2016-08-23 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
| WO2009130198A2 (en) | 2008-04-21 | 2009-10-29 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
| UA40611U (ru) | 2008-05-26 | 2009-04-27 | Владимир Семенович Живченко | Способ десульфурации железоуглеродистого расплава в тигельной печи |
| JP2012501178A (ja) | 2008-08-26 | 2012-01-19 | マクロジェニクス，インコーポレーテッド | Ｔ細胞受容体抗体およびその使用方法 |
| EP2233499A1 (en) | 2009-03-26 | 2010-09-29 | CSL Behring AG | Antibody composition with altered Fab sialylation |
| US10087236B2 (en) * | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| CN102812039B (zh) | 2010-02-16 | 2016-01-20 | 诺沃—诺迪斯克有限公司 | 缀合蛋白质 |
| PE20170779A1 (es) | 2010-03-04 | 2017-07-04 | Macrogenics Inc | Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos |
| BR112013003095B1 (pt) * | 2010-08-10 | 2023-03-28 | Glycotope Gmbh | Método para controle da meia-vida em circulação de um anticorpo ou um fragmento ou derivado funcional do mesmo, composições de anticorpo, seu usos e seus métodos de produção |
| AR085302A1 (es) * | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| CN103974619B (zh) | 2011-03-11 | 2017-02-15 | 阿米库斯治疗学公司 | 治疗法布里病的给药方案 |
| TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| EA202091166A1 (ru) | 2013-03-11 | 2021-04-30 | Джензим Корпорейшн | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ |
| IL289918B2 (en) | 2013-03-11 | 2025-07-01 | Genzyme Corp | Site-specific antibody-drug conjugation through glycoengineering |
| HRP20230260T1 (hr) | 2014-03-19 | 2023-04-28 | Genzyme Corporation | Glikoinženjering ciljajućih dijelova specifičan za mjesto |
| AU2015243512B2 (en) | 2014-04-08 | 2020-06-04 | University Of Georgia Research Foundation Inc. | Site-specific antibody-drug glycoconjugates and methods |
| SG11201702786RA (en) | 2014-10-09 | 2017-05-30 | Genzyme Corp | Glycoengineered antibody drug conjugates |
| CN120192414A (zh) | 2019-04-03 | 2025-06-24 | 建新公司 | 具有降低的断裂的抗αβTCR结合多肽 |
-
2014
- 2014-03-10 IL IL289918A patent/IL289918B2/en unknown
- 2014-03-10 KR KR1020247003596A patent/KR20240023184A/ko active Pending
- 2014-03-10 IL IL318672A patent/IL318672A/en unknown
- 2014-03-10 CN CN201480014449.1A patent/CN105189555B/zh active Active
- 2014-03-10 KR KR1020227023776A patent/KR102755090B1/ko active Active
- 2014-03-10 EP EP14718808.0A patent/EP2983701A2/en not_active Withdrawn
- 2014-03-10 WO PCT/US2014/022623 patent/WO2014164503A1/en not_active Ceased
- 2014-03-10 BR BR112015020315A patent/BR112015020315A2/pt not_active Application Discontinuation
- 2014-03-10 IL IL275376A patent/IL275376B2/en unknown
- 2014-03-10 CN CN201910427632.9A patent/CN110256560A/zh active Pending
- 2014-03-10 CN CN202010633677.4A patent/CN111875705B/zh active Active
- 2014-03-10 WO PCT/US2014/022728 patent/WO2014164534A2/en not_active Ceased
- 2014-03-10 KR KR1020157027622A patent/KR102330681B1/ko active Active
- 2014-03-10 BR BR112015020885A patent/BR112015020885A2/pt not_active Application Discontinuation
- 2014-03-10 EP EP14714881.1A patent/EP2970469B1/en active Active
- 2014-03-10 MX MX2015012527A patent/MX370679B/es active IP Right Grant
- 2014-03-10 EP EP22171935.4A patent/EP4098663A1/en active Pending
- 2014-03-10 RU RU2015142992A patent/RU2711935C2/ru active
- 2014-03-10 SG SG10201809779RA patent/SG10201809779RA/en unknown
- 2014-03-10 AU AU2014249224A patent/AU2014249224B2/en active Active
- 2014-03-10 IL IL319584A patent/IL319584A/en unknown
- 2014-03-10 US US14/203,438 patent/US9701753B2/en active Active
- 2014-03-10 HK HK16102347.8A patent/HK1214501A1/zh unknown
- 2014-03-10 RU RU2015143057A patent/RU2708314C2/ru active
- 2014-03-10 EP EP18187892.7A patent/EP3424956A1/en not_active Withdrawn
- 2014-03-10 US US14/203,479 patent/US9580511B2/en active Active
- 2014-03-10 IL IL304738A patent/IL304738B2/en unknown
- 2014-03-10 CA CA2902525A patent/CA2902525C/en active Active
- 2014-03-10 CA CA2902530A patent/CA2902530C/en active Active
- 2014-03-10 JP JP2016501017A patent/JP6739330B2/ja active Active
- 2014-03-10 KR KR1020237003194A patent/KR20230020013A/ko not_active Ceased
- 2014-03-10 EP EP22151876.4A patent/EP4063389A3/en active Pending
- 2014-03-10 SG SG11201506088RA patent/SG11201506088RA/en unknown
- 2014-03-10 KR KR1020157027621A patent/KR102420934B1/ko active Active
- 2014-03-10 JP JP2016501047A patent/JP6588422B2/ja active Active
- 2014-03-10 SG SG11201506086SA patent/SG11201506086SA/en unknown
- 2014-03-10 AU AU2014249290A patent/AU2014249290B2/en active Active
- 2014-03-10 CN CN201480014338.0A patent/CN105228645B/zh active Active
- 2014-03-10 KR KR1020217037637A patent/KR102494631B1/ko active Active
- 2014-03-10 MX MX2015012570A patent/MX370356B/es active IP Right Grant
-
2015
- 2015-09-02 IL IL241084A patent/IL241084B/en unknown
- 2015-09-02 IL IL241085A patent/IL241085B/en active IP Right Grant
- 2015-09-11 MX MX2019014833A patent/MX2019014833A/es unknown
-
2017
- 2017-01-27 US US15/417,648 patent/US10214589B2/en active Active
- 2017-06-05 US US15/614,015 patent/US10494439B2/en active Active
-
2018
- 2018-12-21 AU AU2018282451A patent/AU2018282451B2/en active Active
-
2019
- 2019-01-03 US US16/238,932 patent/US11130816B2/en active Active
- 2019-03-06 JP JP2019040108A patent/JP7121675B2/ja active Active
- 2019-09-11 JP JP2019165052A patent/JP7021159B2/ja active Active
- 2019-10-17 US US16/655,500 patent/US11807690B2/en active Active
-
2021
- 2021-04-14 JP JP2021068088A patent/JP7321206B2/ja active Active
- 2021-05-27 AU AU2021203458A patent/AU2021203458B2/en active Active
- 2021-08-17 US US17/404,412 patent/US12110338B2/en active Active
-
2022
- 2022-02-02 JP JP2022014608A patent/JP7390414B2/ja active Active
-
2023
- 2023-05-01 JP JP2023075428A patent/JP2023099146A/ja active Pending
- 2023-09-07 US US18/463,047 patent/US20240182595A1/en active Pending
- 2023-11-17 JP JP2023195664A patent/JP7650943B2/ja active Active
-
2024
- 2024-07-29 US US18/787,702 patent/US20250066497A1/en active Pending
- 2024-10-03 AU AU2024227085A patent/AU2024227085A1/en active Pending
-
2025
- 2025-03-11 JP JP2025037867A patent/JP2025090711A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512425A5 (enExample) | ||
| JP2015533490A5 (enExample) | ||
| JP2012521217A5 (enExample) | ||
| JP2016512426A5 (enExample) | ||
| JP2012121878A5 (enExample) | ||
| WO2011003557A8 (en) | A complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent | |
| WO2009061996A3 (en) | Antibodies that bind human dendritic and epithelial cell 205 (dec-205) | |
| BR112015020885A2 (pt) | polipeptídeos de ligação hiperglicosilados | |
| JP2014221758A5 (enExample) | ||
| IL186671A (en) | Monoclonal antibodies that bind specifically to the amyloid-cell peptide, methods of making them, pharmaceutical preparations that include them and their use in the manufacture of drugs | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| WO2008090959A1 (ja) | エフェクター活性が増強された遺伝子組換え抗体組成物 | |
| IL180364A (en) | Use of antibodies specifically related to amyloid-beta peptide in the manufacture of drugs for the treatment of diseases characterized by amyloid-beta deficiency, pharmaceutical compositions including them and methods for their preparation and methods for use thereof | |
| JP2012034692A5 (enExample) | ||
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| JP2014508759A5 (enExample) | ||
| JP2012510461A5 (enExample) | ||
| BR112012013431A2 (pt) | composto, composição farmacêutica e seu uso | |
| JP2017507181A5 (enExample) | ||
| JP2016509011A5 (enExample) | ||
| NZ594480A (en) | Methods and compositions for diagnosis and treatment of cancer | |
| JP2014129360A5 (enExample) | ||
| MX2011012122A (es) | Derivados de tiofeno. | |
| JP2009521206A5 (enExample) | ||
| JP2013520996A5 (enExample) |